Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
BRIEF-ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease June 3 (Reuters) - argenx SE ARGX.BR:
ARGENX PRESENTS NEW EFGARTIGIMOD DATA SHOWING LONG-TERM SUSTAINED PATIENT BENEFIT IN MYOSITIS AND SJOGREN’S DISEASE AT EULAR 2026
PHASE 3 UNITY TRIAL TOPLINE RESULTS EXPECTED IN H2 2027
CONTINUOUS EFGARTIGIMOD PATIENTS SHOW MEAN TIS OF 52.19 AT WEEK 52
AT WEEK 72, MEDIAN CLINESSDAI SCORES 2.5 (EFGARTIGIMOD) AND 2 (SWITCH GROUP)
NO NEW SAFETY SIGNALS FOR EFGARTIGIMOD IN LONG-TERM SJOGREN’S DISEASE USE
ALKIVIA+ DATA SHOW EFGARTIGIMOD PROVIDES SUSTAINED IMPROVEMENT AND CONSISTENT SAFETY IN MYOSITIS
RHO+ DATA SHOW MAINTENANCE OF RESPONSE IN SJOGREN’S DISEASE WITH BIWEEKLY DOSING
CROSS-INDICATION ANALYSIS SHOWS CONSISTENT SAFETY PROFILE FOR EFGARTIGIMOD
Source text: nGNE9kjDN9
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))